News

News Subscription

Dec 20. 2023 / Ad hoc announcement
Basilea announces accelerated loan repayment
Read more
Download
Dec 11. 2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
Read more
Download
Nov 20. 2023
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
Read more
Download
Nov 13. 2023 / Ad hoc announcement
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
Read more
Download
Oct 31. 2023 / Ad hoc announcement
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent
Read more
Download
Oct 19. 2023 / Ad hoc announcement
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
Read more
Download
Oct 17. 2023
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
Read more
Download
Oct 02. 2023 / Ad hoc announcement
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
Read more
Download
Sep 28. 2023
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia
Read more
Download
Aug 15. 2023 / Ad hoc announcement
Basilea reports strong revenue and profit growth in first half-year 2023
Read more
Download